Hiroki Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroki Sato has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Hideo Yukioka
3 shared publicationsKana Watanabe
3 shared publicationsKiyoshi Yoshida
3 shared publicationsKyouhei Hayashi
3 shared publicationsNaoki Omori
3 shared publicationsTakayuki Okuno
3 shared publications
Latest Publications
- Open Access
- 1 May 2020
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 59 (5) , 1043-1051.e2
Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer
- 1 May 2020
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 59 (5) , 1043-1051.e2
Open AccessPatients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer
- Open Access
- 24 June 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (10) , 4883-4891
Incidence of opioid‐induced constipation in Japanese patients with cancer pain: A prospective observational cohort study
This multicenter, prospective, observational cohort study assessed opioid induced constipation (OIC) in Japanese patients with cancer. Eligible patients had stable cancer and an ECOG PS of 0‐2. OIC incidence based on the Rome IV diagnostic criteria was determined by patient diary entries during the first 14 days of opioid therapy. The proportion of patients with OIC was calculated for each 1‐week period and the overall 2‐week study period. Secondary measurements of OIC included the Bowel Function Index (BFI) score (patient assessment administered by physician), spontaneous bowel movements (SBMs) per week (patient assessment), and physician assessments. Medication for constipation was allowed. Two hundred and twenty patients were enrolled. The mean morphine‐equivalent dose was 22 mg/day. By Rome IV criteria, the cumulative incidence of OIC was 56% (95% CI: 49.2%‐62.9%); week 1, 48% (95% CI: 40.8%‐54.6%); week 2, 37% (95% CI: 30.1%‐43.9%). The cumulative incidence of OIC was lower in patients who received prophylactic agents for constipation (48% [95% CI: 38.1%‐57.5%]) than in patients who did not (65% [95% CI: 55.0%‐74.2%]). The cumulative incidences of OIC were 59% (95% CI: 51.9%‐66.0%), 61% (95% CI: 54.3%‐68.1%), and 45% (95% CI: 38.0%‐51.8%) based on BFI scores, physician assessments, and SBM frequency, respectively. Frequency of BMs/week before starting opioids was the most influential factor for the occurrence of OIC. Utilization of prophylactic agents for constipation was associated with a modest effect on reducing the incidence of OIC. The incidences of OIC reported were variable depending on the diagnostic tool involved.
- 24 June 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (10) , 4883-4891
Open AccessIncidence of opioid‐induced constipation in Japanese patients with cancer pain: A prospective observational cohort study
This multicenter, prospective, observational cohort study assessed opioid induced constipation (OIC) in Japanese patients with cancer. Eligible patients had stable cancer and an ECOG PS of 0‐2. OIC incidence based on the Rome IV diagnostic criteria was determined by patient diary entries during the first 14 days of opioid therapy. The proportion of patients with OIC was calculated for each 1‐week period and the overall 2‐week study period. Secondary measurements of OIC included the Bowel Function Index (BFI) score (patient assessment administered by physician), spontaneous bowel movements (SBMs) per week (patient assessment), and physician assessments. Medication for constipation was allowed. Two hundred and twenty patients were enrolled. The mean morphine‐equivalent dose was 22 mg/day. By Rome IV criteria, the cumulative incidence of OIC was 56% (95% CI: 49.2%‐62.9%); week 1, 48% (95% CI: 40.8%‐54.6%); week 2, 37% (95% CI: 30.1%‐43.9%). The cumulative incidence of OIC was lower in patients who received prophylactic agents for constipation (48% [95% CI: 38.1%‐57.5%]) than in patients who did not (65% [95% CI: 55.0%‐74.2%]). The cumulative incidences of OIC were 59% (95% CI: 51.9%‐66.0%), 61% (95% CI: 54.3%‐68.1%), and 45% (95% CI: 38.0%‐51.8%) based on BFI scores, physician assessments, and SBM frequency, respectively. Frequency of BMs/week before starting opioids was the most influential factor for the occurrence of OIC. Utilization of prophylactic agents for constipation was associated with a modest effect on reducing the incidence of OIC. The incidences of OIC reported were variable depending on the diagnostic tool involved.
- Open Access
- 25 November 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_9) , ix130
Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): Patients’ self-assessment of the symptoms and the impact
Background: Opioid-Induced Constipation (OIC) is a common side effect of opioid analgesic therapy. Previously we reported the OIC incidence of cancer patients using Rome IV criteria as the primary outcome of OIC-J Study. This analysis evaluated a patients’ self-awareness of OIC and the burden of OIC.
- 25 November 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_9) , ix130
Open AccessOpioid-induced constipation in patients with cancer pain in Japan (OIC-J study): Patients’ self-assessment of the symptoms and the impact
Background: Opioid-Induced Constipation (OIC) is a common side effect of opioid analgesic therapy. Previously we reported the OIC incidence of cancer patients using Rome IV criteria as the primary outcome of OIC-J Study. This analysis evaluated a patients’ self-awareness of OIC and the burden of OIC.
- Open Access
Association between presenteeism and health-related quality of life among Japanese adults with chronic lower back pain: a retrospective observational study
Objectives This study investigated the relationship between presenteeism and health-related quality of life (HRQoL) among Japanese adults with chronic lower back pain (CLBP). Design This was a retrospective, cross-sectional study. Setting Data were collected via a self-administered online survey of the Japanese adult general population. Participants The present study used 2014 Japan National Health and Wellness Survey (NHWS) data (n=30 000). Specifically, data were included from NHWS respondents who self-reported being employed in the past week and having experienced LBP in the past month, with these symptoms lasting for at least 3 months (n=239). 84 (35.1%) participants in this study were female. Primary and secondary outcome measures Presenteeism and HRQoL were measured using the Work Productivity and Activity Impairment Questionnaire-General Health (categorical (none: 0%, low: 10%–20%, high: ≥30%) and continuous) and Medical Outcomes Study 36-Item Short Form Health Survey, respectively. Covariates included patient demographics, health characteristics, pain characteristics and depression severity (Patient Health Questionnaire). Results Presenteeism was reported by 77.4% of respondents. High (vs no) presenteeism related to more severe pain in the prior week (4.9±2.2 vs 3.6±2.1, p=0.001) and currently (5.1±2.1 vs 3.9±3.9, p=0.007), more pain sites (1.9±1.6 vs 1.1±1.4, p=0.004) and greater depression severity (7.5±6.5 vs 3.6±3.6, pConclusions Most respondents experienced presenteeism. Those with high or low presenteeism had poorer HRQoL than respondents with no presenteeism. Monitoring presenteeism rates may help identify workers with an unmet need for better CLBP-related pain management.
Open AccessAssociation between presenteeism and health-related quality of life among Japanese adults with chronic lower back pain: a retrospective observational study
Objectives This study investigated the relationship between presenteeism and health-related quality of life (HRQoL) among Japanese adults with chronic lower back pain (CLBP). Design This was a retrospective, cross-sectional study. Setting Data were collected via a self-administered online survey of the Japanese adult general population. Participants The present study used 2014 Japan National Health and Wellness Survey (NHWS) data (n=30 000). Specifically, data were included from NHWS respondents who self-reported being employed in the past week and having experienced LBP in the past month, with these symptoms lasting for at least 3 months (n=239). 84 (35.1%) participants in this study were female. Primary and secondary outcome measures Presenteeism and HRQoL were measured using the Work Productivity and Activity Impairment Questionnaire-General Health (categorical (none: 0%, low: 10%–20%, high: ≥30%) and continuous) and Medical Outcomes Study 36-Item Short Form Health Survey, respectively. Covariates included patient demographics, health characteristics, pain characteristics and depression severity (Patient Health Questionnaire). Results Presenteeism was reported by 77.4% of respondents. High (vs no) presenteeism related to more severe pain in the prior week (4.9±2.2 vs 3.6±2.1, p=0.001) and currently (5.1±2.1 vs 3.9±3.9, p=0.007), more pain sites (1.9±1.6 vs 1.1±1.4, p=0.004) and greater depression severity (7.5±6.5 vs 3.6±3.6, pConclusions Most respondents experienced presenteeism. Those with high or low presenteeism had poorer HRQoL than respondents with no presenteeism. Monitoring presenteeism rates may help identify workers with an unmet need for better CLBP-related pain management.
- Open Access
- 27 October 2016
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 17 (1) , 1-9
The impact of depression among chronic low back pain patients in Japan
Chronic low back pain (CLBP) is associated with significant disability and reductions in health related quality of life (HRQoL), which can negatively impact overall function and productivity. Depression is also associated with painful physical symptoms, and is often present in patients with chronic pain. However, the incremental burden associated with depression or symptoms of depression among CLBP patients is not well understood. The objective of this study was to investigate the impact of depression on HRQoL in CLBP and to assess the relationship between depression and work impairment and healthcare use among CLBP patients in Japan. Data were extracted from the 2014 Japan National Health and Wellness Survey (N = 30,000). CLBP was defined by report of diagnosed low back pain ≥3 months duration. Depression was assessed using the Patient Health Questionnaire (PHQ-9). Measurements assessed included pain, HRQoL, labor force participation, work productivity and healthcare utilization. Patients with depression (PHQ-9 ≥ 10) were compared to patients without depression (PHQ-9 < 10) using t-tests for continuous and count variables and chi-square for categorical variables, which were followed by generalized linear models adjusted for covariates. The association between presenteeism and other patient outcomes and characteristics was analysed using nonparametric correlations (Spearman’s rho). Depressed CLBP patients had significantly more severe pain and higher levels of pain compared with patients without depression (P < 0.001). Depression was associated with worse HRQoL in CLBP patients. Presenteeism, overall work impairment and activity impairment were 1.8, 1.9 and 1.7 times as high, respectively, among those with depression relative to those without depression. CLBP patients with depression had almost twice as many healthcare provider visits in 6 months than those without depression. The pattern of results remained consistent after adjustment for sociodemographic and general health characteristics. Analysis also indicated presenteeism was closely related to overall work impairment (rho = 0.99). Depression among CLBP patients in Japan was associated with higher pain scores and lower HRQoL scores, as well as lower labor productivity and increased healthcare use. Screening for depression in CLBP patients should be an essential part of CLBP patient care.
- 27 October 2016
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 17 (1) , 1-9
Open AccessThe impact of depression among chronic low back pain patients in Japan
Chronic low back pain (CLBP) is associated with significant disability and reductions in health related quality of life (HRQoL), which can negatively impact overall function and productivity. Depression is also associated with painful physical symptoms, and is often present in patients with chronic pain. However, the incremental burden associated with depression or symptoms of depression among CLBP patients is not well understood. The objective of this study was to investigate the impact of depression on HRQoL in CLBP and to assess the relationship between depression and work impairment and healthcare use among CLBP patients in Japan. Data were extracted from the 2014 Japan National Health and Wellness Survey (N = 30,000). CLBP was defined by report of diagnosed low back pain ≥3 months duration. Depression was assessed using the Patient Health Questionnaire (PHQ-9). Measurements assessed included pain, HRQoL, labor force participation, work productivity and healthcare utilization. Patients with depression (PHQ-9 ≥ 10) were compared to patients without depression (PHQ-9 < 10) using t-tests for continuous and count variables and chi-square for categorical variables, which were followed by generalized linear models adjusted for covariates. The association between presenteeism and other patient outcomes and characteristics was analysed using nonparametric correlations (Spearman’s rho). Depressed CLBP patients had significantly more severe pain and higher levels of pain compared with patients without depression (P < 0.001). Depression was associated with worse HRQoL in CLBP patients. Presenteeism, overall work impairment and activity impairment were 1.8, 1.9 and 1.7 times as high, respectively, among those with depression relative to those without depression. CLBP patients with depression had almost twice as many healthcare provider visits in 6 months than those without depression. The pattern of results remained consistent after adjustment for sociodemographic and general health characteristics. Analysis also indicated presenteeism was closely related to overall work impairment (rho = 0.99). Depression among CLBP patients in Japan was associated with higher pain scores and lower HRQoL scores, as well as lower labor productivity and increased healthcare use. Screening for depression in CLBP patients should be an essential part of CLBP patient care.
- Open Access
- 1 January 2015
- Published by Japanese Association of Mycotoxicology in JSM Mycotoxins
- Vol. 65 (1) , 7-9
Evaluation of toxicities of 7-hydroxyisotrichodermin and 8-hydroxyisotrichodermin, shunt intermediates in the biosynthetic grid of deoxynivalenol, by using a sensitive yeast assay
- 1 January 2015
- Published by Japanese Association of Mycotoxicology in JSM Mycotoxins
- Vol. 65 (1) , 7-9
Open AccessEvaluation of toxicities of 7-hydroxyisotrichodermin and 8-hydroxyisotrichodermin, shunt intermediates in the biosynthetic grid of deoxynivalenol, by using a sensitive yeast assay
- 1 January 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (1) , 90-95
Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile
- 1 January 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (1) , 90-95
Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile
- 1 November 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (21) , 6554-6558
Identification of a novel and orally available benzimidazole derivative as an NPY Y5 receptor antagonist with in vivo efficacy
- 1 November 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (21) , 6554-6558
Identification of a novel and orally available benzimidazole derivative as an NPY Y5 receptor antagonist with in vivo efficacy
- 1 September 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (17) , 5498-5502
Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles
- 1 September 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (17) , 5498-5502
Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles
- Open Access
- 1 November 2005
- Published by Elsevier in Tetrahedron
- Vol. 61 (47) , 11078-11106
Total synthesis of zaragozic acid C by an aldol-based strategy
- 1 November 2005
- Published by Elsevier in Tetrahedron
- Vol. 61 (47) , 11078-11106
Open AccessTotal synthesis of zaragozic acid C by an aldol-based strategy